Prescription medicine
Atezolizumab Brand names: Tecentriq
Atezolizumab (Tecentriq) is a prescription medicine with an FDA approval on record since 2016. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the atezolizumab FDA label on DailyMed (effective May 20, 2026, Genentech, Inc.); the BLA 761034 record on Drugs@FDA; every atezolizumab label on DailyMed.
Highlights of the record
FDA label of May 20, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageTECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-authorized test.
Forms and strengths
- 840 mg/14ml
- 1200 mg/20ml
Injection (solution).
On the market
- Earliest approval on file
- May 18, 2016 Tecentriq, Genentech Inc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 1 since 2019 0 Class I among all firms' recalls; latest June 12, 2019
- FAERS reports
- 38,607 through July 30, 2026
What is atezolizumab used for?
From the label: indications and usageTECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-authorized test. ( 1.1 , 14.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%] ), as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations. […]
Conditions named in the indications of atezolizumab's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Programmed Death Receptor-1 Blocking Antibody.
Source: FDA drug label (TECENTRIQ), Genentech, Inc., effective May 20, 2026 (SPL set 6fa682c9-a312-4932-9831-f286908660ee), via openFDA; the full label on DailyMed
What does the patient leaflet for atezolizumab say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about TECENTRIQ?TECENTRIQ is a medicine that may treat certain cancers by working with your immune system. TECENTRIQ can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during your treatment or even after your treatment has ended. […] These are not all of the signs and symptoms of immune system problems that can happen with TECENTRIQ. Call or see your healthcare provider right away for any new or worsening signs or symptoms, including: chest pain, irregular heartbeat, shortness of breath, swelling of ankles confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight persistent or severe muscle pain or weakness, muscle cramps low red blood cells, bruising Infusion reactions that can sometimes be severe or life-threatening. […]
Source: FDA drug label (TECENTRIQ), Genentech, Inc., effective May 20, 2026 (SPL set 6fa682c9-a312-4932-9831-f286908660ee), via openFDA; the full label on DailyMed
Is there a generic for atezolizumab (Tecentriq)?
No generic atezolizumab is approved (Drugs@FDA, October 8, 2026).
- 2016 earliest approval on file
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
Has atezolizumab been recalled?
The FDA's Enforcement Report lists 1 recall naming atezolizumab since 2019: 0 Class I (the most serious), 1 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| June 12, 2019 | Class II | Infusion Options, Inc. | Lack of Assurance of Sterility |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the atezolizumab label say about other medicines?
The atezolizumab label names 3 other medicines in its interaction, contraindication or warning sections. The labels of 1 other medicine name atezolizumab. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Cobimetinib | warnings and precautions | TECENTRIQ in Combination with Cobimetinib and Vemurafenib: Immune-mediated pneumonitis occurred in 13% (29/230) of patients receiving TECENTRIQ in combination with cobimetinib and vemurafenib, including Grade 3 (1.3%) and Grade 2 (7%) adverse reactions. |
| Prednisone | warnings and precautions | In general, if TECENTRIQ requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. |
| Vemurafenib | warnings and precautions | TECENTRIQ in Combination with Cobimetinib and Vemurafenib: Immune-mediated pneumonitis occurred in 13% (29/230) of patients receiving TECENTRIQ in combination with cobimetinib and vemurafenib, including Grade 3 (1.3%) and Grade 2 (7%) adverse reactions. |
Other labels that name atezolizumab
Source: FDA drug label (TECENTRIQ), Genentech, Inc., effective May 20, 2026 (SPL set 6fa682c9-a312-4932-9831-f286908660ee), via openFDA; the full label on DailyMed
What do FAERS reports show for atezolizumab?
The FDA Adverse Event Reporting System holds 38,607 reports that list atezolizumab among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 9,820 are coded as a death and 16,374 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as atezolizumab?
16 other medicines are given the same way (intravenous) and in the same FDA class as atezolizumab or labeled mainly for the same use (lung cancer), the same class first. Lung cancer lists all 55 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Nivolumab | Lung cancer | none listed | n/a | No current entry |
| Pembrolizumab | Lung cancer | none listed | n/a | No current entry |
| Pemetrexed | Lung cancer | 15 labelers | n/a | A presentation being discontinued |
| Etoposide | Lung cancer | 5 labelers | n/a | No current entry |
| Topotecan | Lung cancer | 4 labelers | n/a | No current entry |
| Durvalumab | Lung cancer | none listed | n/a | No current entry |
| Ipilimumab | Lung cancer | none listed | n/a | No current entry |
| Ramucirumab | Lung cancer | none listed | n/a | No current entry |
Every medicine labeled for the same conditions as atezolizumab
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to atezolizumab
- 16 medicines for the same use
- Other programmed death receptor-1 blocking antibodys
- the pharmacologic class, with prices and generics
- Atezolizumab side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other